ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 3008 participants.
Also called NCT03462498
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 3,008 participants
- Registry
-
NCT03462498
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Unknown status
Technical summary
Registry record NCT03462498. Randomized; no masking; primary purpose prevention. Start 2018-04-02 (actual); primary completion 2021-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
- Acronym
- STOPDAPT-2 ACS
- Condition
- Acute Coronary Syndrome
- Condition
- Acute Myocardial Infarction
- Condition
- Coronary Artery Disease
- Condition
- Percutaneous Coronary Intervention
- Condition
- Platelet Aggregation Inhibitors
- Intervention (Drug)
- 1-months DAPT
- Intervention (Drug)
- 12-month DAPT
- Lead sponsor
- Kyoto University, Graduate School of Medicine
Record details
- Record id
cardio:ct-nct03462498- Content hash
daad7cdd241ee9e5d0dc68f9eb22fc9dc0bdf448b475caf88afd8f9a385477fe